Dianthus Therapeutics, Inc. $DNTH Shares Sold by Tri Locum Partners LP

Tri Locum Partners LP lessened its position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 76.6% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 145,543 shares of the company’s stock after selling 476,860 shares during the quarter. Dianthus Therapeutics accounts for 1.7% of Tri Locum Partners LP’s portfolio, making the stock its 15th largest position. Tri Locum Partners LP’s holdings in Dianthus Therapeutics were worth $12,214,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of DNTH. PNC Financial Services Group Inc. lifted its holdings in shares of Dianthus Therapeutics by 0.4% during the first quarter. PNC Financial Services Group Inc. now owns 37,360 shares of the company’s stock worth $3,135,000 after purchasing an additional 139 shares during the period. First Horizon Corp purchased a new stake in Dianthus Therapeutics in the first quarter valued at approximately $32,000. Virtus Investment Advisers LLC increased its holdings in Dianthus Therapeutics by 7.1% in the 4th quarter. Virtus Investment Advisers LLC now owns 6,315 shares of the company’s stock worth $260,000 after buying an additional 416 shares during the period. Royal Bank of Canada increased its holdings in Dianthus Therapeutics by 36.9% in the 4th quarter. Royal Bank of Canada now owns 2,012 shares of the company’s stock worth $82,000 after buying an additional 542 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Dianthus Therapeutics by 4.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock worth $280,000 after buying an additional 618 shares during the last quarter. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Dianthus Therapeutics Trading Up 2.4%

Shares of DNTH stock opened at $104.09 on Thursday. The stock has a 50 day moving average of $91.76 and a 200 day moving average of $77.61. The stock has a market cap of $5.69 billion, a P/E ratio of -25.20 and a beta of 1.20. Dianthus Therapeutics, Inc. has a twelve month low of $18.08 and a twelve month high of $107.99.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.22. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%.The company had revenue of $0.46 million during the quarter, compared to the consensus estimate of $0.40 million. On average, research analysts predict that Dianthus Therapeutics, Inc. will post -3.82 earnings per share for the current fiscal year.

Insider Activity

In related news, EVP Simrat Randhawa sold 26,530 shares of the stock in a transaction on Monday, June 1st. The shares were sold at an average price of $90.62, for a total transaction of $2,404,148.60. Following the sale, the executive vice president directly owned 4,000 shares of the company’s stock, valued at approximately $362,480. This represents a 86.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Adam M. Veness sold 30,000 shares of the firm’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $80.80, for a total transaction of $2,424,000.00. Following the sale, the senior vice president owned 30,000 shares in the company, valued at approximately $2,424,000. This represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 87,779 shares of company stock valued at $7,985,235 in the last three months. 3.02% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several analysts have commented on the stock. Wedbush lifted their price objective on shares of Dianthus Therapeutics from $103.00 to $105.00 and gave the company an “outperform” rating in a research note on Wednesday, May 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Friday, July 17th. Guggenheim reissued a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Wall Street Zen upgraded shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, Raymond James Financial reaffirmed a “strong-buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $117.82.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.